Found 6 articles for: "Tapinarof"
Rapid Clearance of Lichen Planus With Topical Tapinarof
April 2026 | Volume 25 | Issue 4 | Case Reports | 381 | Copyright © April 2026
Background: Lichen planus (LP) is an auto-inflammatory idiopathic condition affecting skin, mucous membranes, hair follicles, and nails that presents as pruritic, violaceous papu...
Read MoreAdvanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel
March 2026 | Volume 25 | Issue 3 | Original Article | 221 | Copyright © March 2026
Background: Advanced topical nonsteroidal therapies are expanding options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without many limitations of l...
Read MoreRapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 600 | Copyright © June 2025
Background: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 ye...
Read MoreTreatment of Granuloma Annulare Using Tapinarof Cream 1%
October 2024 | Volume 23 | Issue 10 | Case Reports | 889 | Copyright © October 2024
Granuloma annulare is a benign, non-infectious cutaneous granulomatous disease. Its pathogenesis is not completely elucidatedbut has recently been thought to involve immunologic and ...
Read MoreA Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreDermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials
October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022
Background: Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
